Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06493604 · ClinicalTrials.gov registry record · Phase 3
A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
A Phase 3 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 116
- Enrollment target
NCT06493604 is a Phase 3 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 116 participants.
The verdict
NCT06493604, a Phase 3 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 116 participants
- Enrollment target
Study Summary
A Randomized, Double-Masked, Vehicle-Controlled Parallel Group Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
Interventions
- DRUG Vehicle Ophthalmic Solution
- DRUG Reproxalap Ophthalmic Solution (0.25%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2025-02-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06493604
The ClinicalTrials.gov registry entry for NCT06493604 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle Ophthalmic Solution is the first listed.
NCT06493604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06493604 about?
NCT06493604 is a clinical study titled "A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease". A Randomized, Double-Masked, Vehicle-Controlled Parallel Group Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
What is the current status of trial NCT06493604?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 116 participants. The study started on 2024-06-24. Estimated completion is 2025-02-27.
What interventions are being tested in trial NCT06493604?
The interventions under investigation include: Vehicle Ophthalmic Solution (DRUG), Reproxalap Ophthalmic Solution (0.25%) (DRUG).
Who is sponsoring clinical trial NCT06493604?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.